



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Albert G Hakaim, M.D., MSc, FACS

Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee

Meeting Dates: November 2-3, 2021

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items on November 2, 2021 to discuss and make recommendations on information about the benefit-risk profile of the Endologix AFX endovascular graft system with regards to the risk of Type III endoleaks and on November 3, 2021 to discuss and make recommendations on the continued safety and effectiveness of endovascular stent grafts, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Employer's Grant	SGE's institution involved in sponsor's (Day1) and competitor's product study (Day 2)	Total funding between 25,001 and 50,000 Between \$0 and \$1,000 owed to institution

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

October 7, 2021
Date